NewsRamp Psychedelics Podcast

NewsRamp Psychedelics Podcast

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Episodes

Cybin Inc. Reports Q1 2025 Results and Progress in Depression and Anxiety Studies

August 14, 2025 • 2 mins
Cybin Inc., a clinical-stage neuropsychiatry company, shared its Q1 2025 results and updates on its Phase 3 Depression Program and Phase 2 Anxiety Study. The company has expanded its Phase 3 program for major depressive disorder and is close to completing enrollment for its anxiety study. With adequate funding, Cybin is poised to address the pressing need for improved mental health treatments.
Mark as Played

NRx Pharmaceuticals' HOPE Therapeutics(TM) Expands Network and Expertise with Acquisition of Dura Medical LLC

August 8, 2025 • 2 mins
NRx Pharmaceuticals' subsidiary HOPE Therapeutics(TM) has received regulatory clearance in Florida to acquire Dura Medical LLC, a clinic specializing in mental health and chronic pain treatment. This acquisition will enhance HOPE's presence in Florida and strengthen their capabilities in utilizing psychedelic medications and neuroplastic technologies to treat depression and PTSD. NRx Pharmaceuticals is also progressing with filing ...
Mark as Played

Cybin Inc. Receives European Approval for Phase 3 Study on CYB003 for Major Depressive Disorder

August 7, 2025 • 2 mins
Cybin Inc. has obtained approval to launch the EMBRACE Phase 3 study in Ireland, Poland, and Greece as part of their PARADIGM program. The study will evaluate the efficacy of CYB003, a proprietary deuterated psilocin analog, in treating Major Depressive Disorder by enrolling 330 participants across various international sites. Visit www.cybin.com for more information on Cybin and its innovative mental healthcare research pipeline.
Mark as Played

Revolutionizing Mental Healthcare: Cybin's CEO to Speak at Growth Conference

August 6, 2025 • 2 mins
Cybin Inc., a neuropsychiatry company, will have CEO Doug Drysdale participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. Cybin is dedicated to developing new treatment options for mental health conditions, with ongoing studies on major depressive disorder and generalized anxiety disorder. A live webcast of the event will be available, showcasing Cybin's commitment to transforming mental healthcare.
Mark as Played

Exploring Neuroplasticity in CNS Disorders with NRx Pharmaceuticals CEO

July 29, 2025 • 2 mins
NRx Pharmaceuticals CEO Prof. Jonathan Javitt will discuss the use of ketamine and other drugs for treating CNS disorders like depression, suicidality, and PTSD at the upcoming BTIG Virtual Biotechnology Conference. The company is focused on developing therapeutics for conditions such as bipolar depression and PTSD, with plans to file for Accelerated Approval for NRX-101 and NRX-100.
Mark as Played

Cybin Inc. Receives UK Approval for Phase 3 Trial in Depression

July 17, 2025 • 2 mins
Cybin Inc. has obtained approval to commence the second Phase 3 trial for CYB003 in Depression, aiming to enroll 330 patients globally. With a focus on psychedelic-based treatments, the company seeks to address the growing demand for innovative mental health therapies, following the success of esketamine in the sector.
Mark as Played

NRx Pharmaceuticals Applies for FDA Priority Voucher for NRX-100

June 27, 2025 • 1 min
NRx Pharmaceuticals, trading as NRXP on NASDAQ, has submitted an application for the FDA Commissioner’s National Priority Voucher for their IV Ketamine product, NRX-100. The company's focus on U.S.-based manufacturing and pursuit of a patent on their preservative-free process could enhance their competitive edge in treating suicidal depression and PTSD.
Mark as Played

Advancing FDA-Designated Therapies: NRx Pharmaceuticals Collaborates with IBN for Corporate Communications Strategy

June 25, 2025 • 1 min
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) partners with IBN to enhance investor awareness as it progresses with FDA-designated therapies NRX-100 and NRX-101 for suicidal depression, chronic pain, and PTSD. The company's NMDA platform shows promise in treating central nervous system disorders, with plans for an NDA filing for NRX-100 and a public spin-out of subsidiary HOPE Therapeutics. Stay updated on NRXP developments at https://i...
Mark as Played

Psyence Biomedical Chief to Speak at Psychedelic Science 2025 Conference

June 18, 2025 • 2 mins
Mary-Elizabeth Gifford, Chief of Global Impact at Psyence Biomedical Ltd., will be a featured speaker at Psychedelic Science 2025, discussing business ethics in the realm of psychedelic research. Psyence Biomedical is a Nasdaq-listed biopharma company focusing on nature-derived psilocybin medicine for FDA approval.
Mark as Played

Advancements in Cybin Inc.'s Phase 3 Psychedelic Therapeutics Program

June 13, 2025 • 2 mins
Cybin Inc. provided an update on its Phase 3 Psychedelic Therapeutics Program, highlighting progress in the clinical pipeline, with the lead candidate CYB003 advancing into Phase 3 development. CEO Doug Drysdale expressed confidence in the company's IP portfolio and clinical strategy, noting positive shifts in regulatory sentiment as a key factor in expediting the review process. Cybin is focused on creating safe and effective psyc...
Mark as Played

Innovations in Psychedelic Therapeutics: Updates from Cybin Inc., NRx Pharmaceuticals Inc., and Silo Pharma Inc.

June 12, 2025 • 4 mins
Cybin Inc. CEO Doug Drysdale will be speaking at the H.C. Wainwright Neuro Perspectives Conference and the Psychedelic Science 2025 Conference, highlighting the company's focus on developing psychedelic-based therapeutics for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. has filed an application for a preservative-free ketamine formulation to address the shortage of ketamine in the U.S., and Silo Pharma Inc. has rec...
Mark as Played

NRx Pharmaceuticals Announces Acquisition of Kadima Neuropsychiatry Institute and Plans to Launch $100 Million Psychiatry Clinic Network

June 5, 2025 • 3 mins
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, has acquired Kadima Neuropsychiatry Institute to establish a network of interventional psychiatry clinics. The subsidiary, HOPE Therapeutics, aims to open up to 30 clinics by 2025, with a projected $100 million run rate. NRx has also filed an ANDA for its preservative-free IV ketamine formulation, NRX-100, targeting the U.S. ketamine market and seeking to broaden its ...
Mark as Played

Empower Your Audience with Rythmia: Join the Affiliate Program Today!

June 3, 2025 • 2 mins
Rythmia Life Advancement Center's new affiliate program targets wellness influencers, healers, and marketers to promote its life-changing experiences in Costa Rica. Offering competitive commissions and second-tier referral earnings, partners can share in Rythmia's mission of healing and transformation while earning income. Visit Rythmia's website for more details on this unique opportunity.
Mark as Played

Cybin Inc. Secures U.S. Patent for CYB004 Anxiety Treatment Candidate

June 3, 2025 • 1 min
Cybin Inc. has obtained a U.S. patent for its CYB004 anxiety treatment candidate, extending exclusivity through 2040. CEO Doug Drysdale emphasized the potential of CYB004 to provide rapid-acting, short-duration treatment with a patient-friendly delivery system. The compound is in Phase 2 trials, projected to conclude by mid-2025, solidifying Cybin's position as a frontrunner in innovative mental health therapies.
Mark as Played

Biotech Updates: Incannex Healthcare, Lophora, and NRx Pharmaceuticals

May 28, 2025 • 3 mins
Stonegate Capital Partners provided an update on Incannex Healthcare Inc., reporting reduced expenses and strengthened financial position. Lophora initiated a Phase 1 trial for LPH-5 targeting CNS disorders, aiming to provide therapeutic benefits without hallucinogenic effects. NRx Pharmaceuticals announced a $10.3 million financing to expand its HOPE Clinic Network and advance FDA drug approval for neuroplastic therapies.
Mark as Played

Advancement in PTSD Treatment: Silo Pharma's Nasal Spray Device Study

May 21, 2025 • 1 min
Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studie...
Mark as Played

Advancements in Psychedelic Therapeutics: Cybin Inc., Republican Lawmakers, and Silo Pharma Inc.

May 20, 2025 • 3 mins
Cybin Inc. is making progress in Phase 3 and Phase 2 trials for psychedelic therapeutics targeting mental health conditions, supported by FDA approval. Republican lawmakers like Rep. Morgan Luttrell are advocating for therapeutic use of psychedelics for veterans, while Silo Pharma Inc. recently closed a public offering to fund their research in psychiatric disorders and CNS diseases.
Mark as Played

Biopharmaceutical Companies Silo Pharma Inc. and NRx Pharmaceuticals, Inc. Make Advancements in Drug Development and Financials

May 16, 2025 • 3 mins
Silo Pharma Inc. has priced a public offering of common stock and warrants to raise $2 million, supporting its work on therapeutic treatments for psychiatric disorders and chronic pain. Meanwhile, NRx Pharmaceuticals, Inc. reported a Q1 net loss decrease, progress on ketamine and bipolar depression treatments, and funding for its psychiatry clinic subsidiary.
Mark as Played

Advancements in Psychedelic-Based Therapeutics by Cybin Inc., Silo Pharma Inc., and NRx Pharmaceuticals Inc.

May 15, 2025 • 5 mins
Cybin Inc. partners with Thermo Fisher Scientific for manufacturing of CYB003, a deuterated psilocin treatment for major depressive disorder. Silo Pharma Inc. collaborates with Veloxity Labs for bioanalysis supporting a PTSD treatment, while NRx Pharmaceuticals reports financial results post the acquisition of Kadima Neuropsychiatry Institute. All three companies focus on developing psychedelic-based therapeutics for mental health ...
Mark as Played

Advancing Research on THC-Infused Beverages and Protecting Access to 7-OHM: Industry Initiatives in Focus

May 7, 2025 • 2 mins
Love Yer Brain, part of Iconic Tonics, is collaborating with MoreBetter to study the impact of THC-infused beverages, aiming to provide insights into consumer preferences for alcohol alternatives. Meanwhile, the 7-HOPE Alliance has been established to protect legal access to 7-hydroxymitragynine (7-OHM) and promote responsible usage through science and advocacy efforts.
Mark as Played

Popular Podcasts

    New Heights with Jason & Travis Kelce

    New Heights with Jason & Travis Kelce

    Football’s funniest family duo — Jason Kelce of the Philadelphia Eagles and Travis Kelce of the Kansas City Chiefs — team up to provide next-level access to life in the league as it unfolds. The two brothers and Super Bowl champions drop weekly insights about the weekly slate of games and share their INSIDE perspectives on trending NFL news and sports headlines. They also endlessly rag on each other as brothers do, chat the latest in pop culture and welcome some very popular and well-known friends to chat with them. Check out new episodes every Wednesday. Follow New Heights on the Wondery App, YouTube or wherever you get your podcasts. You can listen to new episodes early and ad-free, and get exclusive content on Wondery+. Join Wondery+ in the Wondery App, Apple Podcasts or Spotify. And join our new membership for a unique fan experience by going to the New Heights YouTube channel now!

    Dateline NBC

    Dateline NBC

    Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

    On Purpose with Jay Shetty

    On Purpose with Jay Shetty

    I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!

    The Breakfast Club

    The Breakfast Club

    The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy, Jess Hilarious, And Charlamagne Tha God!

    The Bobby Bones Show

    The Bobby Bones Show

    Listen to 'The Bobby Bones Show' by downloading the daily full replay.

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

Explore

iHeart

Live Radio

Podcasts

Artist Radio

Exclusives

News

Features

Events

Contests

Photos

Information

About

Advertise

Blog

Brand Guidelines

Contest Guidelines

Subscription Offers

Jobs

Get the App

Automotive

Home

Mobile

Wearables

© 2025 iHeartMedia, Inc.